A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

July 18, 2025

Study Completion Date

July 18, 2025

Conditions
Advanced Chronic Liver DiseaseHealthy Participants
Interventions
DRUG

AZD2389

Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered with bupropion.

DRUG

Midazolam

"Single oral dose on:~* Day 1 (co-administered with caffeine)~* Day 14 (co-administered with caffeine and AZD2389)"

DRUG

Caffeine

"Single oral dose on:~* Day 1 (co-administered with midazolam)~* Day 14 (co-administered with midazolam and AZD2389)"

DRUG

Bupropion

"Single oral dose on:~* Day 2 (alone)~* Day 15 (co-administered with AZD2389)"

Trial Locations (1)

21225

Research Site, Brooklyn

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY